The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Sullivan Mark since 2023.
This trader's CIK number is 1331843.
At the time of last reporting, Sullivan Mark was the Chief Legal Officer of Definium Therapeutics, Inc.. (stock ticker symbol DFTX).
Also see all insider trading activities at Definium Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | SESN | 0 | $0 | 259,049 | $152,060 | 298,175 | $175,028 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | DFTX | 0 | $0 | 10,702 | $197,665 | 0 | $0 |
| 2025 | DFTX | 0 | $0 | 40,621 | $380,891 | 0 | $0 |
| 2024 | DFTX | 0 | $0 | 22,284 | $155,396 | 0 | $0 |
1. Carisma Therapeutics Inc. (SESN)
2. Definium Therapeutics, Inc. (DFTX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-03-02 | SESN | Option Ex | 298,175 | .59 | 175,028 |
| 2023-03-02 | SESN | Sale | 219,218 | .59 | 128,680 |
| 2023-02-21 | SESN | Sale | 39,831 | .59 | 23,380 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-25 | DFTX | Sale | 10,702 | 18.47 | 197,665 |
| 2025-12-26 | MNMD | Sale | 11,276 | 13.15 | 148,245 |
| 2025-09-25 | MNMD | Sale | 11,278 | 9.77 | 110,186 |
| 2025-06-25 | MNMD | Sale | 11,491 | 6.80 | 78,138 |
| 2025-03-25 | MNMD | Sale | 6,576 | 6.74 | 44,322 |
| 2024-09-25 | MNMD | Sale | 4,430 | 5.98 | 26,491 |
| 2024-06-25 | MNMD | Sale | 17,854 | 7.22 | 128,905 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sullivan Mark (Chief Legal Officer of Definium Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.